Avalo Therapeutics Inc (AVTX)

Finanzdaten der Avalo Therapeutics Inc-Aktie (AVTX)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Costs And Expenses	50.79%31.52	20.90	19.80	19.20	19.32
Operating Income/Loss	50.79%-31.52	-20.90	-19.74	-19.20	-19.32
Nonoperating Income/Loss	475.92%-4.82	1.28	6.15	-11.42	-1.43
Income/Loss From Continuing Operations Before Tax	85.24%-36.34	-19.62	-13.59	-30.61	-20.75
Income Tax Expense/Benefit, Deferred	41.67%0.02	0.01	0.13	0.01	0.02
Income Tax Expense/Benefit	50.00%0.02	0.01	0.13	0.01	0.02
	85.22%-36.36	-19.63	-13.72	-30.63	-20.77
Attributable To Parent	85.22%-36.36	-19.63	-13.72	-30.63	-20.77
Available To Common Stockholders, Basic	85.22%-36.36	-19.63	-	-30.63	-20.77
Basic Average Shares	116.85%43.60	20.11	-	14.00	10.83
Diluted Average Shares	116.85%43.60	20.11	-	14.00	10.83
Basic Earnings Per Share	15.31%-0.83	-0.98	-	-2.19	-1.92
Diluted Earnings Per Share	15.31%-0.83	-0.98	-	-2.19	-1.92